Iambic Announces Pricing of Initial Public Offering

Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Iambic. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Iambic, are expected to be $150.0 million. In addition, Iambic has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Iambic’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol “IAM.” The offering is expected to close on October 16, 2026, subject to the satisfaction of customary closing conditions.